Apollo Gleneagles Hospitals

Kolkata, India Listed
Operates a chain of multispeciality hospitals offering comprehensive care.
Request Access
Report Incorrect Data
Page last updated

About Apollo Gleneagles Hospitals

Apollo Gleneagles Hospitals is a publicly listed company based in Kolkata (India) by Prathap Reddy. It operates a chain of multispeciality hospitals offering comprehensive care. It operates on a B2C model. The company has 1,426 employees. Its Indian entity Apollo Hospitals Enterprise Limited reported revenue of ₹25,465 Cr. Its focus areas include Medical Services, Hospitals and Multispeciality Care. Similar companies include Fortis Healthcare, Ujala Cygnus and Narayana Health; 2 of its 3 listed similar companies have raised funding.

Company details

Apollo Gleneagles Hospitals operates a chain of multispeciality hospitals offering comprehensive care, focusing on providing healthcare solutions, medical services, hospitals, and multispeciality care. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets. It continues to evolve, meeting industry challenges with strategic approaches.

Operational Areas
Healthcare → Hospitals & Clinical Care
Key Metrics
  • Market Cap
    ₹1,20,362 Cr

    APOLLOHOSP · NSE

  • Share Price
    ₹8,446.00

    +0.90% today

  • Revenue
    ₹25,228 Cr

    FY 2025-26 · +15.8% YoY

  • EBITDA
    ₹3,750 Cr

    Margin 14.9%

  • Net Profit
    ₹1,869 Cr

    FY 2025-26 · +37.8% YoY

  • P/E (TTM)
    58.8x

    P/B 13.0x

  • ROE
    22.6%

    ROCE 18.1%

  • Debt / Equity
    0.69

    Interest cover 15.6x

  • Employee Count
    1,426

Board of directors of Apollo Hospitals Enterprise Limited (Apollo Gleneagles Hospitals)

Apollo Hospitals Enterprise Limited is the primary company behind Apollo Gleneagles Hospitals. The board of Apollo Hospitals Enterprise Limited currently have 10 directors; the longest-serving is Pratap Chandra Reddy, appointed in 1979. 20 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Pratap Chandra Reddy
DIN 00003654
Whole-time director05 Dec 197946 yrs 11 moApollo Hospitals Enterprise Limited
Preetha Reddy
DIN 00001871
Whole-time director03 Feb 199333 yrs 9 moApollo Hospitals Enterprise Limited
Suneeta Reddy
DIN 00001873
Managing Director01 May 200026 yrs 6 moApollo Hospitals Enterprise Limited
Konda Sangita Reddy
DIN 00006285
Whole-time director03 Feb 201115 yrs 9 moApollo Hospitals Enterprise Limited
Shobana Kamineni
DIN 00003836
Director02 Jul 201412 yrs 4 moApollo Hospitals Enterprise Limited
Pudugramam Murali Doraiswamy
DIN 08235560
Director27 Sep 20188 yrs 1 moApollo Hospitals Enterprise Limited
Velagapudi Kavitha Dutt
DIN 00139274
Director09 Feb 20197 yrs 8 moApollo Hospitals Enterprise Limited
Bhaskara Mandavilli Nageswara Rao
DIN 00287260
Director09 Feb 20197 yrs 8 moApollo Hospitals Enterprise Limited
Som Mittal
DIN 00074842
Director21 Jul 20215 yrs 3 moApollo Hospitals Enterprise Limited
Rama Bijapurkar
DIN 00001835
Director12 Nov 20214 yrs 11 moApollo Hospitals Enterprise Limited

People of Apollo Gleneagles Hospitals

1 people are tracked at Apollo Gleneagles Hospitals (1 in leadership); the tracked headcount is 1,426.

NameRoleGroup
Prathap Reddy
Founder, ChairmanLeadership
Premium access

Complete people profiles for Apollo Gleneagles Hospitals

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Apollo Gleneagles Hospitals

Apollo Gleneagles Hospitals is a publicly listed company on the NSE with ticker symbol APOLLOHOSP in India, operating in the Healthcare sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: APOLLOHOSP
  • Listed entityApollo Hospitals Enterprise Limited
  • Exchange sectorHealthcare

Financials of Apollo Gleneagles Hospitals

Exchange-reported figures of Apollo Hospitals Enterprise Limited, the listed company behind Apollo Gleneagles Hospitals (NSE: APOLLOHOSP).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹25,228 Cr
+15.8% YoY
EBITDA
₹3,750 Cr
+24.1% YoY
Profit After Tax
₹1,869 Cr
+37.8% YoY
Net Worth
₹9,485 Cr
-11.0% YoY
Total Assets
₹18,610 Cr
+11.7% YoY
Total Debt
₹8,488 Cr
+56.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue25,22821,79419,05916,61214,66310,56011,247
Revenue growth+15.8%+14.4%+14.7%+13.3%+38.9%-6.1%-
EBITDA3,7503,0222,3912,0502,1851,1371,587
EBITDA margin+14.9%+13.9%+12.5%+12.3%+14.9%+10.8%+14.1%
Profit before tax2,6612,0391,3801,1441,578221660
Net profit1,8691,356874810836110326
Net profit margin+7.4%+6.2%+4.6%+4.9%+5.7%+1.0%+2.9%
EPS (₹)135.03100.5562.4956.9673.4110.4632.68
Balance sheet
Total assets18,61016,65412,75411,55710,6129,5759,450
Net worth9,48510,6626,9356,1975,6234,6023,339
Total debt8,4885,4155,3334,3324,0684,1603,596
Cash & bank1,1171,360934776924724467
Net working capital2,7942,0511,0471,6161,4331,062978
Cash flow
Cash from operations2,8562,1361,9201,3771,6961,2651,293
Cash from investing(2,145)(3,383)(1,537)(857)(747)(880)(289)
Cash from financing(478)1,319(311)(633)(792)(340)(910)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue7,6156,9326,6066,4776,1895,8425,5925,527
Revenue growth (YoY)+23.0%+18.7%+18.1%+17.2%+10.7%+14.9%--
Other income57.8061.3054.0067.7060.8053.8071.6069.10
EBITDA1,1911,0681,011946918852770762
EBITDA margin+15.6%+15.4%+15.3%+14.6%+14.8%+14.6%+13.8%+13.8%
Depreciation230222224219205215211185
Interest11410811911398.60108115110
Profit before tax904799722682675583516536
Tax245188170166181142101157
Net profit660610551516494441414379
EPS (₹)43.7940.3736.7634.9433.2030.1027.1025.89
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue9,3268,2027,2746,5256,0984,6549,794
Revenue growth+13.7%+12.8%+11.5%+7.0%+31.0%-52.5%-
EBITDA2,3172,0441,7981,6821,4137041,415
EBITDA margin+24.8%+24.9%+24.7%+25.8%+23.2%+15.1%+14.5%
Profit before tax1,9461,6881,3291,22894591.00682
Net profit1,4071,2029821,073654110358
Net profit margin+15.1%+14.7%+13.5%+16.4%+10.7%+2.4%+3.7%
EPS (₹)103.8090.1570.2775.4446.267.3033.78
Balance sheet
Total assets13,15611,82610,9399,4558,8698,2588,570
Net worth9,9638,7347,7116,9256,1115,2023,988
Total debt3,1903,0903,2222,5202,7523,0503,160
Cash & bank349594342318557408346
Net working capital4329041,9011,9171,9399081,005
Cash flow
Cash from operations2,0591,7421,1911,2241,2019161,096
Cash from investing(1,413)(1,046)(835)(588)(504)(781)(264)
Cash from financing(537)(739)(297)(779)(577)(176)(771)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,9032,6562,4382,3642,3562,1682,0752,055
Revenue growth (YoY)+23.2%+22.5%+17.5%+15.0%+10.3%+11.9%--
Other income11147.1090.3010814132.5091.60108
Total expenses2,1802,0001,8431,7821,7631,6221,5541,543
EBITDA723656596582593546521512
EBITDA margin+24.9%+24.7%+24.4%+24.6%+25.2%+25.2%+25.1%+24.9%
Depreciation141134128127122123130108
Interest71.2068.3063.4061.7057.9058.8063.1062.00
Profit before tax622501494502554397420449
Tax14611611211813489.7086.60108

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 07 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue7,6156,9326,6066,4776,1895,8425,5925,527
Revenue growth (YoY)+23.0%+18.7%+18.1%+17.2%+10.7%+14.9%--
Other income57.8061.3054.0067.7060.8053.8071.6069.10
EBITDA1,1911,0681,011946918852770762
EBITDA margin+15.6%+15.4%+15.3%+14.6%+14.8%+14.6%+13.8%+13.8%
Depreciation230222224219205215211185
Interest11410811911398.60108115110
Profit before tax904799722682675583516536
Tax245188170166181142101157
Net profit660610551516494441414379
EPS (₹)43.7940.3736.7634.9433.2030.1027.1025.89
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue25,22821,79419,05916,61214,66310,56011,247
Revenue growth+15.8%+14.4%+14.7%+13.3%+38.9%-6.1%-
Other income23623312690.30372106225
Total expenses21,47818,77216,66814,56312,4789,4239,660
Employee cost3,0002,7692,4942,1771,7861,6011,853
EBITDA3,7503,0222,3912,0502,1851,1371,587
EBITDA margin+14.9%+13.9%+12.5%+12.3%+14.9%+10.8%+14.1%
Depreciation876758687615601573620
Interest450458449381379449533
Profit before tax2,6612,0391,3801,1441,578221660
Tax65853444625647784.70225
Net profit1,8691,356874810836110326
Net profit margin+7.4%+6.2%+4.6%+4.9%+5.7%+1.0%+2.9%
EPS (₹)135.03100.5562.4956.9673.4110.4632.68
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital76.902,52271.9071.9071.9071.9069.60
Reserves & surplus9,4088,1406,8646,1265,5514,5313,270
Shareholders' funds (net worth)9,48510,6626,9356,1975,6234,6023,339
Minority interest494441385334280200131
Secured loans3,1862,8133,1462,5812,6072,8383,163
Unsecured loans5,3022,6012,1861,7511,4611,321433
Total debt8,4885,4155,3334,3324,0684,1603,596
Total liabilities18,61016,65412,75411,55710,6129,5759,450
Assets
Gross block18,25116,19014,20212,48211,7269,62110,231
Net block12,27210,9889,6648,5208,2966,7787,432
Capital work in progress1,03292187361045.50234236
Investments2,1792,4879865748161,343434
Inventories542481460390432250738
Sundry debtors3,4853,0162,5152,2341,7651,3311,027
Cash & bank balances1,1171,360934776924724467
Loans & advances739740687645439338340
Total current assets5,8835,5974,5964,0453,5592,6442,572
Total current liabilities3,0893,5463,5492,4282,1271,5821,594
Net working capital2,7942,0511,0471,6161,4331,062978
Total assets18,61016,65412,75411,55710,6129,5759,450
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash578506433546389381286
Net cash from operating activities2,8562,1361,9201,3771,6961,2651,293
Net cash from investing activities(2,145)(3,383)(1,537)(857)(747)(880)(289)
Net cash from financing activities(478)1,319(311)(633)(792)(340)(910)
Net change in cash23372.6072.10(113)15844.5094.50
Closing cash1,1171,360934776924724467
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+15.8%+14.4%+14.7%+13.3%+38.9%-6.1%-
EBITDA growth+24.1%+26.4%+16.6%-6.2%+92.1%-28.3%-
PBT growth+30.5%+47.7%+20.7%-27.5%+615.0%-66.6%+77.1%
Net income growth+37.8%+55.1%+7.9%-3.0%+658.9%-66.3%-
Revenue CAGR (3Y)+14.9%+14.1%+21.8%+13.9%+15.1%+8.6%+15.7%
EBITDA CAGR (3Y)+22.3%+11.4%+28.1%+8.9%+27.1%+12.8%+29.6%
Profitability & leverage
Net income margin+7.9%+6.9%+4.9%+5.3%+7.5%+1.3%+3.9%
Return on capital employed+18.1%+17.5%+15.5%+14.2%+16.7%+6.5%+11.9%
Return on net worth+22.6%+19.9%+14.3%+15.0%+17.3%+2.4%+9.2%
Debt / equity0.690.610.740.710.810.981.09
Long-term debt / equity0.470.490.580.610.730.830.87
Interest cover15.6420.2526.3826.5523.9079.6055.07
Efficiency & per share
Fixed asset turnover1.471.431.431.371.371.061.34
Inventory turnover49.3146.3444.8540.4243.0421.3917.01
Debtors turnover7.767.888.038.319.478.9610.97
EPS (₹)135.03100.5562.4956.9673.4110.4632.68
Dividend per share (₹)20.0012.6616.0015.0011.753.006.00
Book value per share (₹)659.26571.09481.75430.43390.51319.52239.32
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,9032,6562,4382,3642,3562,1682,0752,055
Revenue growth (YoY)+23.2%+22.5%+17.5%+15.0%+10.3%+11.9%--
Other income11147.1090.3010814132.5091.60108
Total expenses2,1802,0001,8431,7821,7631,6221,5541,543
EBITDA723656596582593546521512
EBITDA margin+24.9%+24.7%+24.4%+24.6%+25.2%+25.2%+25.1%+24.9%
Depreciation141134128127122123130108
Interest71.2068.3063.4061.7057.9058.8063.1062.00
Profit before tax622501494502554397420449
Tax14611611211813489.7086.60108
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue9,3268,2027,2746,5256,0984,6549,794
Revenue growth+13.7%+12.8%+11.5%+7.0%+31.0%-52.5%-
Other income372348180152140148175
Total expenses7,0106,1585,4764,8434,6863,9508,379
Employee cost1,6861,5971,4251,2721,1501,2181,519
EBITDA2,3172,0441,7981,6821,4137041,415
EBITDA margin+24.8%+24.9%+24.7%+25.8%+23.2%+15.1%+14.5%
Depreciation500449399367363421482
Interest242254250239244340426
Profit before tax1,9461,6881,3291,22894591.00682
Tax454392318143280(14.00)212
Net profit1,4071,2029821,073654110358
Net profit margin+15.1%+14.7%+13.5%+16.4%+10.7%+2.4%+3.7%
EPS (₹)103.8090.1570.2775.4446.267.3033.78
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital71.9071.9071.9071.9071.9071.9069.60
Reserves & surplus9,8918,6627,6396,8536,0395,1303,919
Shareholders' funds (net worth)9,9638,7347,7116,9256,1115,2023,988
Secured loans1,8221,7831,9561,6562,0242,2812,852
Unsecured loans1,3671,3061,266865728768308
Total debt3,1903,0903,2222,5202,7523,0503,160
Total liabilities13,15611,82610,9399,4558,8698,2588,570
Assets
Gross block10,6779,6608,9367,6397,3887,0258,146
Net block6,9166,3486,0325,0785,1215,0386,056
Capital work in progress32030620096.4023.90219227
Investments4,8933,9112,6212,2172,0592,0911,076
Inventories14712711998.30147210707
Sundry debtors8478158088208241,204966
Cash & bank balances349594342318557408346
Loans & advances4925511,7221,6231,426259268
Total current assets1,8352,0872,9922,8592,9542,0822,288
Total current liabilities1,4031,1831,0909421,0161,1731,283
Net working capital4329041,9011,9171,9399081,005
Total assets13,15611,82610,9399,4558,8698,2588,570
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash233276217360239280219
Net cash from operating activities2,0591,7421,1911,2241,2019161,096
Net cash from investing activities(1,413)(1,046)(835)(588)(504)(781)(264)
Net cash from financing activities(537)(739)(297)(779)(577)(176)(771)
Net change in cash109(42.90)59.10(143)120(41.20)61.50
Closing cash349594342318557408346
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+13.7%+12.8%+11.5%+7.0%+31.0%-52.5%-
EBITDA growth+13.3%+13.7%+6.9%+19.0%+100.7%-50.3%-
PBT growth+15.3%+27.1%+8.2%+29.9%+938.5%-86.7%+47.5%
Net income growth+17.0%+22.4%-8.4%+64.0%+495.6%-69.4%-
Revenue CAGR (3Y)+12.7%+10.4%+16.1%-12.7%-9.9%-13.5%+15.8%
EBITDA CAGR (3Y)+11.3%+13.1%+36.7%+5.9%+11.5%-5.3%+22.3%
Profitability & leverage
Net income margin+16.0%+15.8%+13.9%+16.6%+10.9%+2.3%+4.8%
Return on capital employed+17.5%+17.1%+15.5%+16.0%+12.6%+3.6%+12.1%
Return on net worth+16.0%+15.8%+13.8%+16.6%+11.6%+2.4%+9.1%
Debt / equity0.340.380.390.400.510.680.81
Long-term debt / equity0.310.350.350.370.470.570.65
Interest cover13.3115.9317.8618.1623.25120.3145.65
Efficiency & per share
Fixed asset turnover0.920.880.880.870.850.611.47
Inventory turnover68.2266.8767.0453.2434.1510.1415.44
Debtors turnover11.2210.118.937.946.014.2910.45
EPS (₹)103.8090.1570.2775.4446.267.3033.78
Dividend per share (₹)20.0012.6616.0015.0011.753.006.00
Book value per share (₹)692.85607.39536.22481.56424.94361.72286.52

Similar companies to Apollo Gleneagles Hospitals

Apollo Gleneagles Hospitals has 3 listed similar companies in our database, 2 of them funded. They include Fortis Healthcare, Ujala Cygnus and Narayana Health.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Fortis Healthcare
fortishealthcare.com1996Gurugram, India1,565
Multi-specialty hospital services are provided across India by Fortis Healthcare.
Ujala Cygnus
ujalacygnus.com2011Delhi, India$36.74M2,084
A chain of multi-specialty hospitals is operated in India.
Narayana Health
narayanahealth.org2000Bengaluru, India$148.2M8,145
A chain of multi-specialty hospitals is operated in India.
Premium access

Detailed similar companies of Apollo Gleneagles Hospitals

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Apollo Gleneagles Hospitals

Websites that share an audience with Apollo Gleneagles Hospitals (apollogleneagles.in).

Similar websites

Websites whose visitors overlap most with Apollo Gleneagles Hospitals. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
apollosaltlake.com
apollosaltlake.com
100%
–
kolkata.apollohospitals.com
kolkata.apollohospitals.com
100%
–
Aherf
aherf.org
84%
#14,522,895View details
apollohospdelhi.com
apollohospdelhi.com
84%
–
apollohealthcity.com
apollohealthcity.com
84%
–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 21 similar websites and full traffic analytics for Apollo Gleneagles Hospitals

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 21 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Hospitals & Clinical Care

3 companies that operate in the same segment as Apollo Gleneagles Hospitals (Hospitals & Clinical Care) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Cloudnine
Maternity, childcare, and fertility services are delivered via hospital chains.
2007Bengaluru, Karnataka, IndiaUSD 204.87 MUSD 140.46 M4,459
HCG
Chain of oncology hospitals
1989Bengaluru, Karnataka, IndiaUSD 36.59 MUSD 270.51 M321
Medanta
Chain of multi-super specialty healthcare hospitals
2004Gurugram, Haryana, IndiaUSD 104.7 MUSD 461.72 M12,240
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Apollo Gleneagles Hospitals

Apollo Hospitals: CLSA on Apollo Hospitals maintains Outperform, Target Price Rs 9860; Q2 revenue grew 23% YoY, with healthy growth across segments and a 70bps improvement in margins. Capacity additions of 4718 census beds by FY31 remain on track, with 520 beds already commissioned. Healthcare margins are expected to improve from 24%, supported by established hospitals and breakeven at newer units.
Exchange Update • 2 days ago
Apollo Hospitals: JPMorgan on Apollo Hospitals maintains Overweight, Target Price Rs 10700; Q2 revenue and EBITDA grew 23% and 29% YoY, respectively, with revenue 2% ahead of consensus. Hospital demand remained strong, with occupancy rising 400bps to 73%, inpatient volumes growing 14% and ARPP increasing 8%. New-unit losses and pre-operative costs weighed on margins. HealthCo's demerger remains on track for Q4FY27, while digital health achieved cash breakeven.
Exchange Update • 2 days ago
Apollo Hospitals: Co' Apollo HealthCo Lowers Q4 FY27 Margin Expectation To About 6% Due To One-Time Costs, But Anticipates Higher Single-Digit Margins In Three To Four Years.
Exchange Update • 2 days ago
Apollo Hospitals: Citi on Apollo Hospitals maintains Buy, Target Price Rs 10770; Q2 consolidated revenue, EBITDA and PAT grew 23%, 29% and 32% YoY, respectively. Hospitals revenue increased 23%, driven by 14% inpatient volume growth and an 8% rise in ARPP, while HealthCo EBITDA grew 75% and its digital business turned cash-positive for the first time. Strong hospital demand, improving HealthCo profitability and the bed-expansion pipeline support the outlook, while oncology trade-margin caps and regulatory notices remain key areas to monitor.
Exchange Update • 3 days ago
Apollo Hospitals: Sees Opportunities For Larger Profit Margins In Hospital Operations
Exchange Update • 3 days ago
APOLLOHOSP: Q2 REVENUE 76.15B RUPEES VS 62B (YOY)
Exchange Update • 4 days ago
APOLLOHOSP: Q2 CONS NET PROFIT 6.3B RUPEES VS 4.77B (YOY); EST 6.3B
Exchange Update • 4 days ago
APOLLOHOSP: Q2 EBITDA 11.9B RUPEES VS 9.4B (YOY); Q2 EBITDA MARGIN 15.64% VS 14.93% (YOY)
Exchange Update • 4 days ago
Kerala Government Plans New Bill To Control Private Hospital Fees, Says Health Minister.
Exchange Update • 13 days ago
APOLLOHOSP: RS. 54.48 CRORES BSE BLOCK TRADE; FOR ~ 69,400 SHARES, AT RS. 7850.00
Exchange Update • 1 month ago
Premium access

Complete news archive for Apollo Gleneagles Hospitals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Apollo Gleneagles Hospitals

Apollo Gleneagles Hospitals is headquartered in Kolkata, India. It is registered at Kolkata, West Bengal, India.

Apollo Gleneagles Hospitals has 1,426 employees.

The primary company behind Apollo Gleneagles Hospitals, Apollo Hospitals Enterprise Limited, reported revenue of ₹25,465 Cr for FY 2026, up 16% year on year.

Apollo Gleneagles Hospitals operates a chain of multispeciality hospitals offering comprehensive care, focusing on providing healthcare solutions, medical services, hospitals, and multispeciality care. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets. It continues to evolve, meeting industry challenges with strategic approaches.

Apollo Gleneagles Hospitals's top competitors include Fortis Healthcare, Ujala Cygnus and Narayana Health.

Yes, Apollo Gleneagles Hospitals is publicly traded on NSE under the ticker symbol APOLLOHOSP.

Apollo Gleneagles Hospitals operates through Apollo Hospitals Enterprise Limited.

The legal entities of Apollo Gleneagles Hospitals currently have 12 directors, including Pratap Chandra Reddy, Shobana Kamineni, Konda Sangita Reddy and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available